5. Which of the following statements BESTdescribes the significant findings SWOG 9346 clinical (intermittent
versus continuous androgendeprivation therapy inmetastaticprostate cancer)?
a. Intermittentandrogendeprivation therapyhasdemonstratednon-inferiorsurvival in themetastaticsetting.
b. Health-relatedquality-of-life scores in thedomainsofmentalhealth, erectiledysfunctionand libidowere
improvedatearly timepoints (3and9months) inpatients treatedwith intermittentandrogendeprivation
therapy.
c. Cardiovascular healthoutcomes are improved inpatients on intermittent androgendeprivation.
d. Bonehealth is improved inpatients on intermittent androgendeprivation.
6. A 70-year-oldman withmetastatic CRPC involving bone presents to the emergency department unable to
functionathomewith fatigue,nauseaandvomiting,andanorexia. He isreceiving treatmentwithdepotgoserelin,
hydrocortisone20mgpoqamand10mgpoqpm,zoledronicacid4mgIVevery3weeks,andstartedketoconazole
for risingPSA2weeks ago. Routine complete blood count and serumbiochemistry arenormal except formild
anemia,mildelevation inBUN, andAST3xULN,ALT4XULN. PSA is78ng/mLandwas69ng/mL2weeks
ago. Themost likelyexplanation is:
a. Hepaticmetastasesdue toCRPCprogressionhavedeveloped.
b. Hepatic toxicityof ketoconazole.
c. Nausea andvomitingdue to zoledronic acid therapy.
d. Hypoadrenalism secondary toketoconazole.
7. Bonescanswitheither technetium-99m labeledphosphonateorfluorine-18 labeledfluorideareuseful for:
a. Evaluatingbonemetastases.
b. Measuring response to therapy.
c. Both a andb.
d. Neither aor b.
8. PET/CTwithfluorine-18 labeledFDG isuseful for:
a. Evaluatingbonemetastases.
b. Measuring response to therapy.
c. Both a andb.
d. Neither aor b.
9.Whichof the following is true concerning sipuleucel-T administration?:
a. It is contraindicatedwithvisceralmetastasis.
b. ThePSA levelmust begreater than 10.0ng/mLbeforeuse.
c. Premedicationwith acetaminophen anddiphenhydraminewill limit adverse reactions.
d. It is given subcutaneouslyweekly for a total of threeweeks.
10.What is theprocess for preparing sipuleucel-T?
a. Sipuleucel-T is anautologous immunotherapy that relies on ex-vivo stimulationof dendritic cells by the
patients autologousprostate cancer cells.
b. Removal and concentrationof dendritic cellswith re-infusionof the cells alongwithGMCSF.
c. Stimulationof thepatientwith IVGMCSFandPAPantigenswith collectionofdendritic cells. The cellsare
concentratedand then reinfused.
d. Removal of dendritic cells fromapatient and reinfusionafterprocessingand expansionwithGMCSFand
PAPconstructs.
POST-TESTFORCME
A12
©TheCanadian Journal ofUrology™: International Supplement, April 2014
